Resources for your practice

CRYSVITA for TIO Start Guide

This step-by-step guide provides information for initiating, dosing, and administering CRYSVITA as well as guidance for patients and caregivers.

Download the CRYSVITA for TIO Start Guide >

CRYSVITA for TIO Start Guide

This step-by-step guide provides information for initiating, dosing, and administering CRYSVITA as well as guidance for patients and caregivers.

CRYSVITA Start Guide for healthcare providers, patients, and caregivers

UltraCare Start Form

Download and complete the UltraCare Start Form with your patient.

Download the UltraCare Start Form >

UltraCare Start Form

Download and complete the UltraCare Start Form with your patient.

UltraCare Start Form for patients

CRYSVITA for TIO Patient Brochure

Download this Patient Brochure to provide your patients with information about TIO treatment with CRYSVITA.

Download the CRYSVITA for TIO Patient Brochure >

CRYSVITA for TIO Patient Brochure

Download this Patient Brochure to provide your patients with information about TIO treatment with CRYSVITA.

CRYSVITA® resources & patient brochure

Connect with a community of support for tumor-induced osteomalacia (TIO)

NIH Genetic and Rare Diseases Information Center (GARD)
GARD maintains a list of rare diseases and related terms to help people find reliable information about their disease.

GARD is resource that maintains a list of rare diseases and related terms to help people find information about their disease

National Organization for Rare Disorders (NORD)
NORD is a patient advocacy organization dedicated to individuals with rare diseases and the organizations that serve them.

NORD is a patient advocacy organization committed to helping patients with rare diseases

CRYSVITA Proposed Mechanism of Action Video

×

Glossary

antibody

A protein that is made by the immune system or a protein that is modified in a lab to recognize and block a target that threatens the body’s normal function.

baseline

The beginning of the study before patients are given any treatment.

bone histomorphometry

A method of assessing bone quality from bone biopsy samples. Histomorphometry includes assessments of osteoid volume to bone volume, osteoid thickness, and mineralization lag times.

fibroblast growth factor 23 (FGF23)

A protein that plays a role in phosphate homeostasis. In TIO, the excess circulating FGF23 leads to increased signaling, resulting in impaired phosphate uptake.

mineralization

A process where minerals like phosphorus are deposited in the bone, causing the bone to harden.

mineralization lag time (MLt)

The interval between osteoid formation and osteoid mineralization. In TIO, mineralization lag times are long, pointing to abnormalities in the process of bone mineralization.

neoplasm

An abnormal growth of tissue in some part of the body.

osteoid

The bone matrix; an unmineralized component of bone.

osteoid thickness (O.Th)

A measurement of the amount of unmineralized bone.

osteoid volume/bone volume (OV/BV)

A ratio of unmineralized bone to mineralized bone. In TIO, this ratio is large, pointing to a greater presence of unmineralized bone.

osteomalacia

A softening and weakening of the bones in adults caused by deficiencies in vitamin D, calcium, or phosphate. In children, osteomalacia can occur simultaneously with rickets.

phosphaturic mesenchymal tumor

A tumor that produces FGF23 and often causes hypophosphatemia.

phosphorus

A mineral that is important for proper bone development and repair.

serum phosphorus

Amount of phosphorus in the blood.